Neumora Therapeutics Inc (NASDAQ: NMRA) started the day on Thursday, with a price increase of 3.14% at $10.50, before settling in for the price of $10.18 at the close. Taking a more long-term approach, NMRA posted a 52-week range of $8.33-$21.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 55.65%. This publicly-traded company’s shares outstanding now amounts to $160.48 million, simultaneously with a float of $55.35 million. The organization now has a market capitalization sitting at $1.70 billion. At the time of writing, stock’s 50-day Moving Average stood at $11.81, while the 200-day Moving Average is $11.63.
Neumora Therapeutics Inc (NMRA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Neumora Therapeutics Inc’s current insider ownership accounts for 65.74%, in contrast to 29.79% institutional ownership. According to the most recent insider trade that took place on Oct 18 ’24, this organization’s Director sold 14,049 shares at the rate of 17.03, making the entire transaction reach 239,319 in total value, affecting insider ownership by 20,100. Preceding that transaction, on Oct 17 ’24, Company’s Director sold 7,739 for 17.01, making the whole transaction’s value amount to 131,643. This particular insider is now the holder of 20,100 in total.
Neumora Therapeutics Inc (NMRA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
Neumora Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 55.65% and is forecasted to reach -1.64 in the upcoming year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Let’s observe the current performance indicators for Neumora Therapeutics Inc (NMRA). It’s Quick Ratio in the last reported quarter now stands at 10.98. The Stock has managed to achieve an average true range (ATR) of 0.72.
In the same vein, NMRA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.85, a figure that is expected to reach -0.44 in the next quarter, and analysts are predicting that it will be -1.64 at the market close of one year from today.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
If we take a close look at the recent performances of Neumora Therapeutics Inc (NASDAQ: NMRA), its last 5-days Average volume was 0.78 million that shows progress from its year to date volume of 0.75 million. During the previous 9 days, stock’s Stochastic %D was recorded 54.47% While, its Average True Range was 0.70.
Raw Stochastic average of Neumora Therapeutics Inc (NMRA) in the period of the previous 100 days is set at 14.78%, which indicates a major fall in contrast to 63.03% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 48.60% that was lower than 67.86% volatility it exhibited in the past 100-days period.
